IL17A and inflammatory bowel disease: An unmet need for more effective oral therapies, such as IL-23 inhibitors and possibly IL-17 inhibitors, if they do not exacerbate or trigger inflammatory bowel disease, are well suited to fill this niche by offering higher efficacy while maintaining a manageable safety profile.